Circulating tumour DNA sequencing reveal mechanisms of resistance to BRAF-targeted therapies in BRAF-mutated gastrointestinal stromal tumour
- PMID: 36470024
- DOI: 10.1016/j.ejca.2022.10.018
Circulating tumour DNA sequencing reveal mechanisms of resistance to BRAF-targeted therapies in BRAF-mutated gastrointestinal stromal tumour
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment on
-
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.Eur J Cancer. 2021 Mar;145:132-142. doi: 10.1016/j.ejca.2020.12.008. Epub 2021 Jan 16. Eur J Cancer. 2021. PMID: 33465704 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials